SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Durelli, L.
Right arrow Articles by Bergamasco, B
Right arrow Search for Related Content
PubMed
Right arrow Articles by Durelli, L.
Right arrow Articles by Bergamasco, B
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects

Luca Durelli

Clinica delle Malattie del Sistema Nervoso

MR Bongioanni

Clinica delle Malattie del Sistema Nervoso

B Ferrero

Clinica delle Malattie del Sistema Nervoso

D Imperiale

Clinica delle Malattie del Sistema Nervoso

E Verdun

Clinica delle Malattie del Sistema Nervoso

A Oggero

Clinica delle Malattie del Sistema Nervoso

E Gentile

Clinica delle Malattie del Sistema Nervoso

GB Bradac

Cattedra di Neuroradiologia, Universita’ di Torino, Via Cherasco, 15, 1–10126 Torino, Italy

M Bergui

Cattedra di Neuroradiologia, Universita’ di Torino, Via Cherasco, 15, 1–10126 Torino, Italy

L Bergamini

Clinica delle Malattie del Sistema Nervoso

B Bergamasco

Clinica delle Malattie del Sistema Nervoso

Twenty relapsing-remitting (RR) clinically definite MS patients were treated with 9 MIU intramuscular recombinant interferon alpha-2a (rIFNA) (Rof eron-A, Roche) (n=12) or placebo (n=8) every other day for 6 months and followed up for a further 6 months after stopping treatment Numbers of active lesions at MRI and of patients with clinical-MRI signs of disease activity and lymphocyte interferon gamma production, which were decreased during treatment, returned to values similar to baseline and placebos after stopping treatment rIFNA chronic therapy seems therefore needed in order to maintain drug efficacy. Side effect prof ile was monitored, too, for over 1 year in the same 20 patients plus 25 additional RR MS patients. Besides the typical side effects of type 1 interferon therapy (fever, fatigue, depression, lymphopenia, hepatic enzyme elevation), occurrence of serum autoAbs was noted in 30% patients (in 60% antinuclear and in 80% antithyroid autoAbs). In two patients rIFNA treatment was stopped, in one case for antithyroid autoAbs and hypothyroidism, in the other for antinuclear autoAbs and a five-fold increase of ALT. A careful monitoring of serum autoAbs and of signs of thyroid or liver damage must always precede and accompany longterm type 1 IFN therapy.

Key Words: multiple sclerosis • clinical trials • interferon alpha-2a • side effects • magnetic resonance imaging • cytokines

Multiple Sclerosis, Vol. 1, No. 6, 366-371 (1996)
DOI: 10.1177/135245859600100617
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement